drugset / Trial / NCT00421200

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

NCT00421200

Phase 3 Completed 375 enrolled Sangart
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Hemospan is superior to Voluven for preventing hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and postoperative complications including organ dysfunction and failure until follow-up at one month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically evaluate the safety data collected during this trial.

Timeline

Start
2007-02
Primary completion
2008-05
Completion
2008-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hemospan Protein / enzyme biologic 250 ml
Comparator hydroxyethyl starch Other / unclassified 250 ml